Foust Richard J. 4

What Happened

• Richard J. Foust, President & CEO and Director of Mobia Medical, was awarded a derivative security on 2026-05-07 covering 666,670 underlying shares. The Form 4 records the acquisition at $0.00 (derivative award), so no cash was paid and no sale occurred.

Key Details

• Transaction date: 2026-05-07; Form filed: 2026-05-11 (filed within the standard two-business-day window).
• Transaction type: Award/Grant (derivative security) — coded "A" on the filing.
• Amount: 666,670 underlying shares; acquisition price recorded as $0.00; total value shown as $0 on the Form 4.
• Vesting: 25% of the underlying shares vest on May 7, 2027, then the remainder vests in 36 substantially equal monthly installments (per footnote).
• Shares owned after transaction: not specified in the excerpt of the filing provided.
• Exercise price or other economic terms (if any) are not detailed in the summary provided; the filing records this as a grant of derivative securities (options/rights) rather than an immediate stock purchase.

Context

• This was an equity award (derivative grant), not an open-market purchase or sale. Such grants typically represent potential future ownership as the award vests and, if applicable, is exercised; they are not immediately liquid stock. The vesting schedule means benefits are earned over time rather than all at once.